Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1228

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1228
---
 over the shares held by Benuvia. The principal executive office of Benuvia is 3950 N.
    Mays Street Round Rock, TX 78665.

Securities
Authorized for Issuance under Equity Compensation Plans

    Plan
    Category
     
    Number
    of
    Securities to Be 
    Issued upon 
    Exercise of 
    Outstanding 
    Options, Warrants 
    and Rights (2)

    Weighted
    Average
    Exercise Price of 
    Outstanding 
    Options, 
    Warrants and 
    Rights (2)

    Number
    of Securities 
    Remaining Available for 
    Future Issuance under 
    the Plan (excluding 
    securities reflected in 
    column (a) (2))

    (a)

    (b)

    (c)

    Equity
    compensation plans approved by security holders (1)

    925,449

    $
    5.95

    1,018,995

    Equity
    compensation plans not approved by security holders

    Total

    1,018,995

    (1)
    Represents
    the shares of Common Stock authorized for issuance under the 2023 Plan.  In February 2024, the board
    of directors approved an amendment to the 2023 Plan, subject to stockholder approval
    which was subsequently obtained. An aggregate of 3,000,000 shares were originally authorized for issuance under the 2023 Plan, and
    after the amendment and our Reverse Stock Split in connection with the IPO, an aggregate of 444,444 shares have been authorized
    under the 2023 Plan. On June 12, 2024, the board of directors authorized an amendment to the 2023 Plan to increase
    the number of shares of Common Stock authorized for issuance thereunder by 1,500,000 from 444,444 shares
    to 1,944,444 shares. On October 22, 2024, the increase in the number of shares in the 2023 Plan was approved
    by the affirmative vote of a majority of the outstanding shares of Common Stock present in person, by remote communication,
    if applicable, or represented by proxy at the Annual Meeting.  As of March
    26, 2025, options to purchase an aggregate of 925,449
    shares of our Common Stock with a weighted-average exercise price